Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 15/20 | 0.84 |
| ▸ | KLK1 | P06870 | 7/20 | 0.84 |
| ▸ | F2 | P00734 | 7/20 | 0.84 |
| ▸ | TMPRSS15 | P98073 | 7/20 | 0.42 |
| ▸ | TMPRSS2 | O15393 | 3/20 | 0.41 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.41 |
| ▸ | HPN | P05981 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | SLC47A2 | Q86VL8 | 2/20 | 0.41 |
| ▸ | SLC47A1 | Q96FL8 | 2/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3245051 | 0.91 | PRSS1 (1.00) | PRSS1KLK1F2TMPRSS15TMPRSS2 | |
| SCHEMBL7311244 | 0.91 | PRSS1 (1.00) | PRSS1KLK1F2TMPRSS15TMPRSS2 | |
| Acetic Acid SCHEMBL7312877 | 0.90 | PRSS1 (0.96) | PRSS1KLK1F2TMPRSS15MEN1 | |
| Acetic Acid SCHEMBL7311943 | 0.90 | PRSS1 (0.96) | PRSS1KLK1F2TMPRSS15MEN1 | |
| SCHEMBL7618252 | 0.87 | PRSS1 (0.82) | PRSS1KLK1F2TMPRSS15MEN1 | |
| SCHEMBL7618254 | 0.87 | PRSS1 (0.82) | PRSS1KLK1F2TMPRSS15MEN1 | |
| SCHEMBL1650235 | 0.87 | PRSS1 (1.00) | PRSS1KLK1F2TMPRSS15MEN1 | |
| Acetic Acid SCHEMBL7622802 | 0.86 | PRSS1 (0.80) | PRSS1KLK1F2TMPRSS15MEN1 | |
| Acetic Acid SCHEMBL7622805 | 0.86 | PRSS1 (0.80) | PRSS1KLK1F2TMPRSS15MEN1 | |
| SCHEMBL7189652 | 0.85 | PRSS1 (0.88) | PRSS1KLK1F2TMPRSS15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159441-A1 | ENZYME-CLEAVABLE METHADONE PRODRUGS AND METHODS OF USE THEREOF | 3I, LP | 2023-05-25 | — | — | US | disclosed |
| US-11154549-B2 | Opioid compositions resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200093817-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2020-03-26 | — | — | US | disclosed |
| US-10335406-B2 | Opioid compositions resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10028945-B2 | Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20170119754-A1 | Compositions Comprising Enzyme-Cleavable Ketone-Modified Opioid Prodrugs and Optional Inhibitors Thereof | 3I, LP | 2017-05-04 | — | — | US | disclosed |
| US-9585963-B2 | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9499581-B2 | Compositions comprising enzyme-cleavable oxycodone prodrug | SIGNATURE THERAPEUTICS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-20130090379-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Tapentadol Prodrug | SIGNATURE THERAPEUTICS, INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20130059914-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120295834-A1 | Opioid Prodrugs with Heterocyclic Linkers | 3I, LP | 2012-11-22 | — | — | US | disclosed |
| US-20120232066-A1 | COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS | SIGNATURE THERAPEUTICS, INC. | 2012-09-13 | — | — | US | disclosed |
| US-20120230916-A1 | Compositions Comprising Enzyme-Cleavable Ketone-Modified Opioid Prodrugs and Optional Inhibitors Thereof | 3I, LP | 2012-09-13 | — | — | US | disclosed |
| US-20120178773-A1 | Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug | 3I, LP | 2012-07-12 | — | — | US | disclosed |
| US-20120178772-A1 | Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug | 3I, LP | 2012-07-12 | — | — | US | disclosed |
| US-20110262355-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110262359-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-20110262360-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof | SIGNATURE THERAPEUTICS, INC. | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200093817-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | PRSS1 952/4885KLK1 3383/4885F2 3807/4885 |
| US-20120230916-A1 | Compositions Comprising Enzyme-Cleavable Ketone-Modified Opioid Prodrugs and Optional Inhibitors Thereof | ACHE, CYP2C18, CYP2C9 | PRSS1 156/4885KLK1 151/4885F2 1160/4885 |
| US-20120295834-A1 | Opioid Prodrugs with Heterocyclic Linkers | OPRK1, OPRM1, PREP | PRSS1 17/4885KLK1 550/4885F2 150/4885 |
| US-20170119754-A1 | Compositions Comprising Enzyme-Cleavable Ketone-Modified Opioid Prodrugs and Optional Inhibitors Thereof | ACHE, CYP2C18, CYP2C9 | PRSS1 156/4885KLK1 151/4885F2 1160/4885 |
| US-20110262360-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Opioid Prodrugs and Inhibitors Thereof | COMT, OPRM1, DNPEP | PRSS1 84/4885KLK1 914/4885F2 1303/4885 |
| US-20180085366-A1 | OPIOID COMPOSITIONS RESISTANT TO OVERDOSE AND ABUSE | OPRM1, OPRK1, OPRD1 | PRSS1 952/4885KLK1 3383/4885F2 3807/4885 |
| US-20130090379-A1 | Compositions Comprising Enzyme-Cleavable Phenol-Modified Tapentadol Prodrug | CYP2C9, ACHE, COMT | PRSS1 247/4885KLK1 1236/4885F2 1981/4885 |
| US-20110262359-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE PRODRUGS OF ACTIVE AGENTS AND INHIBITORS THEREOF | PEPD, TMPRSS15, ADAM17 | PRSS1 27/4885KLK1 919/4885F2 1313/4885 |
| US-20230159441-A1 | ENZYME-CLEAVABLE METHADONE PRODRUGS AND METHODS OF USE THEREOF | CES2, ACHE, COMT | PRSS1 63/4885KLK1 1123/4885F2 2861/4885 |
| US-20120178773-A1 | Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug | OPRK1, CYP3A7, OPRD1 | PRSS1 12/4885KLK1 269/4885F2 2591/4885 |
| US-10335406-B2 | Opioid compositions resistant to overdose and abuse | OPRM1, OPRK1, OPRD1 | PRSS1 952/4885KLK1 3383/4885F2 3807/4885 |
| US-20120232066-A1 | COMPOSITIONS FOR REDUCING RISK OF ADVERSE EVENTS CAUSED BY DRUG-DRUG INTERACTIONS | CYP2C19, CYP3A5, CYP3A4 | PRSS1 124/4885KLK1 1574/4885F2 1376/4885 |
| US-20110262355-A1 | COMPOSITIONS COMPRISING ENZYME-CLEAVABLE OPIOID PRODRUGS AND INHIBITORS THEREOF | ACHE, OPRM1, DNPEP | PRSS1 60/4885KLK1 714/4885F2 1483/4885 |
| US-20130059914-A1 | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof | ACHE, COMT, CES2 | PRSS1 96/4885KLK1 1659/4885F2 4549/4885 |
| US-20120178772-A1 | Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug | OPRK1, KDM8, ADAM8 | PRSS1 45/4885KLK1 243/4885F2 1193/4885 |
| US-11154549-B2 | Opioid compositions resistant to overdose and abuse | OPRM1, OPRK1, OPRD1 | PRSS1 952/4885KLK1 3383/4885F2 3807/4885 |
| US-10028945-B2 | Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof | ACHE, CYP2C18, CYP2C9 | PRSS1 156/4885KLK1 151/4885F2 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.